243 related articles for article (PubMed ID: 32073795)
1. [Continue to use the bivalent HPV vaccine; bivalent vaccine more effective than expected].
Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073795
[TBL] [Abstract][Full Text] [Related]
2. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well].
van Bergen JEAM
Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073799
[TBL] [Abstract][Full Text] [Related]
3. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
7. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
8. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
9. [Diseases caused by human papilloma viruses].
Zollner U; Schwarz TF
Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
[TBL] [Abstract][Full Text] [Related]
10. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
11. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
Joura EA; Pils S
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371
[TBL] [Abstract][Full Text] [Related]
15. Bivalent AS04-adjuvanted HPV vaccine provides optimal cancer prevention for HPV types not included in the vaccine.
Beyer WEP; Osterhaus ADME
Vaccine; 2020 Nov; 38(47):7414-7416. PubMed ID: 33051041
[TBL] [Abstract][Full Text] [Related]
16. HPV vaccines to prevent cervical cancer and genital warts: an update.
Dochez C; Bogers JJ; Verhelst R; Rees H
Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
[TBL] [Abstract][Full Text] [Related]
17. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182
[TBL] [Abstract][Full Text] [Related]
18. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
19. HPV vaccines: their pathology-based discovery, benefits, and adverse effects.
Nicol AF; de Andrade CV; Russomano FB; Rodrigues LS; Oliveira NS; Provance DW; Nuovo GJ
Ann Diagn Pathol; 2015 Dec; 19(6):418-22. PubMed ID: 26321154
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
